Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Evasion of Necroptosis and Inflammasome Activation Promotes Myeloid Leukemogenesis

Ulrike Höckendorf, Dipl. Humanbiol., Yabal Monica, PhD, Christian Peschel, MD, Philipp J. Jost, MD

Blood (2016) 128 (22): 2856.

https://doi.org/10.1182/blood.V128.22.2856.2856

Published: 2016

Journal Articles

A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML

Ingmar Glauche, PhD, Hendrik Liebscher, Christoph Baldow, Matthias Kuhn, Philipp Schulze, Tom Haehnel, Astghik Voskanyan, PhD, Joelle Guilhot, PhD, Stéphanie Dulucq, PhD, Nikolas von Bubnoff, MD, Susanne Saussele, MD, Satu Mustjoki, MD PhD, Philipp J. Jost, MD, Francois Guilhot, MD PhD, François-Xavier Mahon, MD PhD, Ingo Roeder, PhD

Blood (2016) 128 (22): 3099.

https://doi.org/10.1182/blood.V128.22.3099.3099

Published: 2016

Journal Articles

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Andreas Reiter, MD, Gunay Ahmadova, MD, Mohamad Jawhar, MD, Andres Virchis, MD, Tim Somervaille, MDPhD, Mark Williams, MD, Bernd Schönberger, MD, Rebecca Frewin, FRCPath, MRCP, MBBS, BSc, Philipp J. Jost, MD, Annett Maschke, MD, Peter Keller, MD, Torsten Haferlach, MD, Nicole Naumann, Juliana Schwaab, MD, Alice Fabarius, PhD, Wolf-Karsten Hofmann, MD, Claudia Haferlach, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD

Blood (2016) 128 (22): 3114.

https://doi.org/10.1182/blood.V128.22.3114.3114

Published: 2016

Journal Articles

Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure

Stefanie Jilg, MD, Johanna Kauschinger, MDcal student, Veronika Reidel, MDcal student, Catharina Müller-Thomas, MD, Richard Hauch, MDcal student, Johannes Schauwecker, MD, Burkhard Schmidt, MD, Ulrike Höckendorf, Dipl. Humanbiol., Christian Peschel, MD, Katharina Götze, MD, Philipp J. Jost, MD

Blood (2016) 128 (22): 4297.

https://doi.org/10.1182/blood.V128.22.4297.4297

Published: 2016

Journal Articles

A Mouse Model for XLP-2 Disease Uncovers a Critical Function for IL-1beta and TNF in Driving Hyper-Inflammation

Philipp J. Jost, MD, Monica Yabal, PhD, Heiko Adler, PhD, Nathalie Knies, Christina Groß, Rune Busk Damgaard, Hirokazu Kanegane, MD PhD, Christian Peschel, MD, Andreas Strasser, PhD, Olaf Groß, Jürgen Ruland, MD, Mads Gyrd-Hansen, PhD

Blood (2014) 124 (21): 1403.

https://doi.org/10.1182/blood.V124.21.1403.1403

Published: 2014

Journal Articles

cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner

W. Wei-Lynn Wong, James E. Vince, Najoua Lalaoui, Kate E. Lawlor, Diep Chau, Aleksandra Bankovacki, Holly Anderton, Donald Metcalf, Lorraine O’Reilly, Philipp J. Jost, James M. Murphy, Warren S. Alexander, Andreas Strasser, David L. Vaux, John Silke

Blood (2014) 123 (16): 2562–2572.

https://doi.org/10.1182/blood-2013-06-510743

Published: 2014

Includes: Supplemental data

Journal Articles

MCL-1 Critically Regulates Survival Of T-Lymphocyte Non-Hodgkin Lymphoma

Sabine Spinner, Kelly Gemma, PhD, Marco Herold, PhD, Konstanze Pechloff, PhD, Giuliano Crispatzu, Jürgen Ruland, MD, Marco Herling, MD, Christian Peschel, MD, Andreas Strasser, PhD, Philipp J. Jost, MD

Blood (2013) 122 (21): 4246.

https://doi.org/10.1182/blood.V122.21.4246.4246

Published: 2013

Journal Articles

Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications

Philipp J. Jost, Jürgen Ruland

Blood (2006) 109 (7): 2700–2707.

https://doi.org/10.1182/blood-2006-07-025809

Published: 2006

Journal Articles

Functional and Molecular Analysis of Maturation of Thymocytes in Bcl10 or Malt1 Deficient Mice.

Philipp J. Jost, MD, Uta Ferch, Stephanie Weiss, Stephanie Leeder, Olaf Gross, Tak W. Mak, MD, Christian Peschel, MD, Juergen Ruland, MD

Blood (2005) 106 (11): 3323.

https://doi.org/10.1182/blood.V106.11.3323.3323

Published: 2005

NARROW

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Evasion of Necroptosis and Inflammasome Activation Promotes Myeloid Leukemogenesis

A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure

A Mouse Model for XLP-2 Disease Uncovers a Critical Function for IL-1beta and TNF in Driving Hyper-Inflammation

cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner

MCL-1 Critically Regulates Survival Of T-Lymphocyte Non-Hodgkin Lymphoma

Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications

Functional and Molecular Analysis of Maturation of Thymocytes in Bcl10 or Malt1 Deficient Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only